Vivex Biologics has completed enrollment in its ASCEND trial of VIA Disc NP for symptomatic degenerative disc disease (DDD). The randomized, double-blind, sham-controlled study enrolled 110 participants across five Australian sites and will assess pain reduction at six months post-procedure. Topline data is expected in Q1 2026.
This announcement signals Vivex’s intent to accelerate its entry into the interventional pain management market for DDD. The company is pursuing a minimally invasive approach targeting a significant unmet need: effective, non-surgical options for chronic lower back pain. While pharmaceuticals and physical therapy remain first-line treatments, they offer limited relief for many patients, leaving a gap that VIA Disc NP aims to fill. This strategy allows Vivex to bypass the complex regulatory pathway for new drugs, focusing instead on device innovation.
The ASCEND trial design, with its focus on a sham-controlled procedure, highlights the challenges of demonstrating efficacy in pain management. Subjectivity and placebo effects are significant hurdles, requiring rigorous methodology to isolate the true impact of the intervention. This approach also reflects increasing payer scrutiny, demanding clear clinical evidence before reimbursing novel procedures. The trial’s Australian setting may suggest a strategic focus on gaining initial regulatory approval in a market perceived as faster and less costly, potentially serving as a springboard for subsequent FDA submission.
For clinical sites, this development underscores the growing demand for minimally invasive procedures and their integration into routine patient care. The relative simplicity of VIA Disc NP administration could streamline workflows and expand treatment capacity, potentially easing the burden on surgical suites. For sponsors and device manufacturers, Vivex’s strategy emphasizes the continuing opportunity in the DDD market. However, reimbursement hurdles and competition from established players pose considerable challenges.
Moving forward, the Q1 2026 data readout will be critical. The results will not only determine VIA Disc NP’s clinical viability but also influence the trajectory of Vivex’s broader strategy in the pain management sector. Investors and competitors will be watching closely for the magnitude and durability of pain reduction, as well as the incidence of adverse events. The upcoming data will also inform Vivex’s next steps: U.S. regulatory strategy, pricing negotiations with payers, and market access planning. The longer-term implications for surgical intervention and chronic pain management remain to be seen.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
